type 2 diabetes

By Jonah Comstock November 14, 2018
Diabetes management company Virta Health announced today that the company will offer its service to employers and health plans at 100 percent risk — that is, customers will only pay if the company succeeds in its goal of reversing Type 2 diabetes and getting patients off of expensive diabetes medications. “Whoever pays the healthcare bill today, we say to them, 'Wouldn’t it be awesome if we could...
By Dave Muoio October 9, 2018
Health2047, a technology innovation enterprise backed the American Medical Association, announced today the launch of its second spin out company. Called First Mile Care, the new entity will use its $2 million in seed funding to build a scalable platform for connecting people with prediabetes to coaches and demographic-appropriate behavior change guidance. First Mile Care’s platform is being...
By Jonah Comstock September 5, 2018
Correction: A previous version of this article failed to specify that the deal concerns Freestyle Libre Pro, rather than the consumer version, Freestyle Libre. Livongo Health, the digital chronic disease management company founded by former Allscripts CEO Glen Tullman, announced today that it will be the first United States enterprise diabetes management company to bring Abbott’s Freestyle Libre...
By Dave Muoio June 20, 2018
Digital chronic disease management company Omada Health announced today the launch of new programs designed to support individuals with Type 2 diabetes and hypertension. Accompanying these are a set of new features for the enterprise and health plan platform focused on medication adherence and remote monitoring, all of which comprise what a representative from the company described as “the...
By Dave Muoio April 4, 2018
San Francisco-based Virta Health has announced the closing of a $45 million Series B funding round for its digitally-delivered, drug- and surgery-free Type 2 diabetes treatment. Previous investors Venrock, Obvious Ventures, Creandum, Caffeinated Capital, and SciFi VC participated in the round, with new investors including Founders Fund and Playground Global joining as well. Virta’s approach to...
By Dave Muoio March 19, 2018
Veterans with Type 2 diabetes who received remote consultations via telehealth achieved glycemic control that was similar to, but not quite on par with, those attending face-to-face visits. On the flip side, these patients were able to complete their diabetes consultations an average 27 days earlier, offering a potential model for those unable to conveniently receive in-person specialty care,...
By Dave Muoio March 14, 2018
A six-month pilot program conducted by Sharp Rees-Stealy Medical Group in San Diego found that diabetes patients using Glooko’s care management platform were more engaged with their care and achieved better control of their blood glucose levels, according to a case study released by the company. From April to October 2016, Sharp Rees-Stealy care teams provided access to Glooko's platform to 50...
By Dave Muoio March 6, 2018
Samsung Health users will now have access to a new consumer-grade version of WellDoc’s digital diabetes management platform, the two companies announced this morning. The Diabetes Wellness Program is a 12-week wellness program designed to help Type 2 diabetes patients improve unhealthy behaviors and better manage their condition. The program is available through the Samsung Health version 5.14 or...
By Jonah Comstock February 15, 2018
San Francisco-based FareWell is changing its name to Better Therapeutics, a rebranding that reflects the company’s shift in focus from weight loss and disease prevention to digital therapeutics to treat chronic diseases. To punctuate that shift, Better Therapeutics is announcing the name change on the same day as the publication of a study in the Journal of Medical Internet Research that...
By Dave Muoio February 14, 2018
Digital diabetes care company Glooko announced today that its Mobile Insulin Dosing System (MIDS) — an app-driven tool that recommends insulin dose adjustments using data collected directly from a patient’s blood glucose meter — has been cleared by the FDA. The MIDS module allows clinicians to create a customized treatment plan and send it to Type 2 diabetes patients directly through the company’...